TRU-SENTIMENT · DeltaNeutral
NKTR Trading Analysis - 11/06/2026 02:38 PM — TRU-SENTIMENT
Options chain · Stock chart · Baseline chart
NKTR (Nektar Therapeutics) at $37.15. True Sentiment Bullish, delta 40-60 call 100% / put 0%, call $23,710 vs put $0. RSI 52.4.
- Symbol
- NKTR
- Price
- $37.15
- Article bias (separate from True Sentiment)
- bullish
- Conviction
- low
- Published
- 2026-11-06 14:38:00 ET
- Author
- DeltaNeutral staff
TRUE SENTIMENT ANALYSIS (DELTA 40-60 OPTIONS)
True Sentiment Analysis (Delta 40-60 Options)From the embedded TRUE SENTIMENT OPTIONS data:
Call Dollar Volume: $23,710.00 (100.00%) Put Dollar Volume: $0.00 (0.00%) Total: $23,710.00
- Sentiment is Bullish with 24 call contracts vs 0 put contracts, 3 call trades vs 0 put trades.
- Only 3 of 516 total options analyzed met the Delta 40-60 filter (0.60% filter ratio) — small pure directional sample.
- Read suggests near-term upside conviction from directional call buyers despite bearish technicals.
- Divergence: Option spread engine flagged "Options sentiment is Bullish but technicals are Bearish" and advised waiting for alignment.
Key Statistics: NKTR
Fundamental Snapshot
Valuation
| P/E (trailing) | 4.50 |
| EPS (trailing 12 mo) | $-2.87 |
| Market cap | $1.27B |
| Shares outstanding | 34.1M |
Dividend
| Dividend yield | 0.00% |
Risk & range
| Beta | 1.34 |
| 52-week low | $33.40 |
| 52-week high | $109.00 |
| Historical volatility | 90.8% |
Ownership & trading
| Institutional ownership | 45.4% |
| Average daily volume | 0.8M sh |
Reported figures; no analyst estimates.
📈 Analysis
News Headlines & Context
The following items are based on general knowledge of Nektar Therapeutics (NKTR) and are provided as context only, separate from the data-driven analysis below.
- NKTR previously announced strategic pipeline reprioritization focused on its immunology programs, reducing burn but raising questions on late-stage catalysts.
- Recent biotech sector weakness and a broad risk-off move in small-cap pharmaceuticals pressured speculative names including NKTR.
- No confirmed near-term FDA catalyst has been scheduled per public knowledge; any trial readout would be a volatile binary event.
- Context: The embedded data shows a steep multi-week decline from the $60s to high-$30s, consistent with a loss of momentum despite isolated bullish options flow.
Fundamental Analysis
Based strictly on the provided FUNDAMENTALS data:
- Trailing P/E is listed at 4.50, but Trailing EPS is -2.87, indicating the company is not profitable; the positive P/E is non-meaningful due to negative earnings.
- Forward P/E, PEG Ratio, Profit Margins, ROE, Revenue Growth, Total Revenue, and Free Cash Flow are all null — no margin or growth trend can be calculated.
- Market Cap is $1,268,241,735.00 with Shares Outstanding of 34,143,000.00 and Institutional Ownership at 45.41%.
- 52-Week High is $109.00 and 52-Week Low is $33.40; current embedded price (~$36.20) sits near the low end of the annual range.
- Beta is 1.34 and Historical Volatility is 90.78%, reflecting elevated systematic and idiosyncratic risk.
- Analyst consensus, target mean price, and recommendation key are null — no street consensus available in data.
- Fundamentals show a loss-making micro-cap biotech with high volatility and no provided revenue/margin profile, diverging from the bullish options sentiment flagged in the embedded flow.
Current Market Position
From the embedded minute and daily data:
- Daily close on 2026-11-05 was $36.20, down from $38.15 on 2026-11-04 and an intraday low of $35.76.
- Minute bars from 2026-11-05 09:30 to 2026-11-06 14:10 show opening at $38.36, drifting to $37.15 by final bar, with thin late-session volume (7744 then 842).
- Recent daily range low was $35.61 (2026-10-16); current price is just above that structural low.
Technical Analysis
Technical Indicators
- Price ($36.20) is below SMA 5 ($37.54), SMA 20 ($37.92), and far below SMA 50 ($52.70) — bearish alignment with no golden cross.
- RSI at 52.39 is neutral, not confirming strong downside or upside momentum.
- MACD (-3.93) below signal (-3.14) with negative histogram (-0.79) shows bearish momentum persisting.
- Bollinger Bands: price is between lower ($35.48) and middle ($37.92); no squeeze flagged, bands are wide given HV.
- 30-day range high $62.40, low $35.61; price is near the bottom 5% of the 30-day range.
True Sentiment Analysis (Delta 40-60 Options)
From the embedded TRUE SENTIMENT OPTIONS data:
Call Dollar Volume: $23,710.00 (100.00%) Put Dollar Volume: $0.00 (0.00%) Total: $23,710.00
- Sentiment is Bullish with 24 call contracts vs 0 put contracts, 3 call trades vs 0 put trades.
- Only 3 of 516 total options analyzed met the Delta 40-60 filter (0.60% filter ratio) — small pure directional sample.
- Read suggests near-term upside conviction from directional call buyers despite bearish technicals.
- Divergence: Option spread engine flagged "Options sentiment is Bullish but technicals are Bearish" and advised waiting for alignment.
Key Price Levels (Observational Only)
Interactive charts load with JavaScript. This text is the crawlable summary.